Cases & Deals

  • Home
  • Practices
  • Biotheranostics establishes trademark rights for its BREAST CANCER INDEX and CancerTYPE ID tests

Share

Biotheranostics establishes trademark rights for its BREAST CANCER INDEX and CancerTYPE ID tests

October 2019

Client(s) Biotheranostics, Inc.

Jones Day is assisting Biotheranostics, Inc., a commercial-stage molecular diagnostics company, with the branding for its prognostic and predictive tests that support physicians in the treatment of cancer. The Firm’s work includes trademark prosecution and management for Biotheranostics’ portfolio that includes the BREAST CANCER INDEX and CancerTYPE ID trademarks.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.